Hydrobenzamide derivatives as inhibitors of Hsp90

Patent metadata

Field	Value
Publication number	US-9428439-B2
Application number	US-201414149450-A
Country	US
Kind code	B2
Filing date	Jan 7, 2014
Priority date	Oct 12, 2006
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

The invention provides an acid addition salt of a compound of the formula (1). Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogs thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new medical uses of compounds of the formula (1) and its ethyl analog.

First claim

What is claimed is:

1. A method for reducing cancer in a mammal, the method comprising administering to the mammal an effective amount of an acid addition salt of a compound of the formula (1):

which is a salt formed with lactic acid, wherein said cancer is selected from: carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, ovary, pancreas, stomach, thyroid, prostate, gastrointestinal system, skin, a hematopoietic tumor of lymphoid or myeloid lineage, and a tumor of the central or peripheral nervous system.

2. A method of claim 1 wherein the acid addition salt in substantially crystalline form has a crystalline form selected from forms FL1 or FL2.

3. A method for reducing cancer in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising an effective amount of an acid addition salt of a compound of the formula (1):

which is a salt formed with lactic acid, and a pharmaceutically acceptable carrier, wherein said cancer is selected from: carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, ovary, pancreas, stomach, thyroid, prostate, gastrointestinal system, skin, a hematopoietic tumor of lymphoid or myeloid lineage, and a tumor of the central or peripheral nervous system.

4. A method of claim 3 wherein the acid addition salt in substantially crystalline form has a crystalline form selected from forms FL1 or FL2.

5. A method according to claim 3 , wherein said pharmaceutically acceptable carrier is a carrier for intravenous or oral administration.

6. A method according to claim 1 wherein said cancer is selected from: colon adenocarcinoma, colon adenoma, colorectal carcinoma, small cell lung cancer, non-small cell lung carcinoma, exocrine pancreatic carcinoma, gastrointestinal stromal tumors, leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Burkett's lymphoma, acute myelogenous leukaemia, chronic myelogenous leukaemia, Imatinib sensitive and refractory chronic myelogenous leukaemia, myeloproliferative disease, melanoma, bortezomib sensitive multiple myeloma, thyroid follicular cancer and glioma.

7. A method according to claim 1 wherein said cancer is selected from: carcinoma of the prostate, gastrointestinal stromal tumors, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Burkett's lymphoma, acute myelogenous leukaemia, chronic myelogenous leukaemia, bortezomib sensitive multiple myeloma, non-small cell lung cancer, thyroid, follicular cancer, melanoma, and ErbB2-positive breast cancer.

8. A method according to claim 3 wherein said cancer is selected from: colon adenocarcinoma, colon adenoma, colorectal carcinoma, small cell lung cancer, non-small cell lung carcinoma, exocrine pancreatic carcinoma, gastrointestinal stromal tumors, leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Burkett's lymphoma, acute myelogenous leukaemia, chronic myelogenous leukaemia, Imatinib sensitive and refractory chronic myelogenous leukaemia, myeloproliferative disease, melanoma, bortezomib sensitive multiple myeloma, thyroid follicular cancer and glioma.

9. A method according to claim 1 wherein said cancer is selected from: carcinoma of the prostate, gastrointestinal stromal tumors, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Burkett's lymphoma, acute myelogenous leukaemia, chronic myelogenous leukaemia, bortezomib sensitive multiple myeloma, non-small cell lung cancer, thyroid, follicular cancer, melanoma, and ErbB2-positive breast cancer.

10. A method of claim 1 wherein the lactic acid salt is the L-lactate.

11. A method of claim 3 wherein the lactic acid salt is the L-lactate.

Assignees

• Astex Therapeutics Ltd

Inventors

• Frederickson Martyn
• Lyons John Francis
• Thompson Neil Thomas
• Vinkovic Mladen
• Williams Brian John
• Woodhead Andrew James
• Woolford Alison Jo-Anne

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title